TARS logo

Tarsus Pharmaceuticals Inc. (TARS)

$78.68

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on TARS

Market cap

$3.88B

EPS

-15.16

P/E ratio

--

Price to sales

5.65

Dividend yield

--

Beta

0.341529

Price on TARS

Previous close

$80.28

Today's open

$81.35

Day's range

$77.39 - $81.35

52 week range

$53.89 - $91.53

Profile about TARS

CEO

Bobak Azamian

Employees

370

Headquarters

Irvine, CA

Exchange

Nasdaq Global Select

Shares outstanding

49305552

Issue type

Common Stock

TARS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on TARS

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:

news source

GlobeNewsWire • Nov 5, 2026

news preview

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals NASDAQ: TARS reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye care professionals and a growing contribution from retreatment prescriptions.

news source

MarketBeat • Nov 4, 2026

news preview

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Tarsus Reports Third Quarter 2026 Financial Results

Generated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch Appointed Neera Clase as Chief Commercial Officer Management to host conference call today, November 3, 2026, at 1:30 p.m. PT / 4:30 p.m.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to a loss of $0.3 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%

The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

news source

Zacks Investment Research • Nov 2, 2026

news preview

My 'Eye' Is On Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is well-positioned with Xdemvy's rapid commercial ramp and robust $2B peak sales potential. Recent acquisitions of IRX-101 and ALK-101 diversify the pipeline, adding both low-risk and high-reward late-stage assets. IRX-101's clinical data and market need suggest strong approval prospects and $600–900M peak sales, enhancing TARS' valuation case.

news source

Seeking Alpha • Nov 1, 2026

news preview

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.

news source

GlobeNewsWire • Oct 29, 2026

news preview

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served as Tarsus' Interim Chief Commercial Officer since July 2026 and previously served as Senior Vice President of Market Access.

news source

GlobeNewsWire • Oct 28, 2026

news preview

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 27, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Tarsus Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Tarsus Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in TARS on M1